PARIS, France, December 28, 2022 at 8:00 p.m. (CET) – Pharnext SA (FR001400BV89 – ALPHA) (the “Company”), an advanced clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases with no satisfactory therapeutic solution, announces today today a series of decisions aimed at ensuring the next stages of its development with the support of Néovacs (FR00140077X1 – ALNEV), a French biotechnology company specializing in therapeutic vaccines targeting the treatment of autoimmune diseases and support for Promising BioTech and MedTech, following on from the financing and strategic support agreement with Pharnext announced on October 3, 2022.